Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00215800 | The Study of the Safety and Efficacy of Ampligen in Chronic Fatigue Syndrome | PHASE3 | COMPLETED | 234 | — | — | Dec 1, 1998 | Feb 1, 2004 | Apr 17, 2013 | - | — |
| Name | Type | Description |
|---|---|---|
| Ampligen | DRUG | - |
Inclusion Criteria: 1. A diagnosis of CFS, as defined by the Center for Disease Control (1988 CDC case definition) \> 12 months (Appendix D). 2. Age Range: \> 18 years old, \< 60 years old. 3. Males or non-pregnant, non-lactating females: Females must be of non-child bearing potential (either post-...